Oil & Gas Exploration & Production
Build Your Comparison
Side-by-side financial analysisStock Comparison
VET vs CVE vs JPM vs SU vs CNQ
Revenue, margins, valuation, and 5-year total return — side by side.
Oil & Gas Integrated
Banks - Diversified
Oil & Gas Integrated
Oil & Gas Exploration & Production
VET vs CVE vs JPM vs SU vs CNQ — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Oil & Gas Exploration & Production | Oil & Gas Integrated | Banks - Diversified | Oil & Gas Integrated | Oil & Gas Exploration & Production |
| Market Cap | $1.71B | $53.24B | $896.00B | $73.11B | $94.49B |
| Revenue (TTM) | $1.81B | $49.40B | $280.33B | $52.01B | $40.74B |
| Net Income (TTM) | $-814M | $4.64B | $57.05B | $6.33B | $9.71B |
| Gross Margin | 35.9% | 19.6% | 60.0% | 55.5% | 30.8% |
| Operating Margin | 20.2% | 14.0% | 25.9% | 27.4% | 26.8% |
| Forward P/E | 11.2x | 6.2x | 14.4x | 6.8x | 7.5x |
| Total Debt | $1.30B | $17.00B | $942.38B | $18.37B | $19.71B |
| Cash & Equiv. | $19M | $2.74B | $343.34B | $3.65B | $672M |
VET vs CVE vs JPM vs SU vs CNQ — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Vermilion Energy In… (VET) | 100 | 250.0 | +150.0% |
| Cenovus Energy Inc. (CVE) | 100 | 605.4 | +505.4% |
| JPMorgan Chase & Co. (JPM) | 100 | 341.0 | +241.0% |
| Suncor Energy Inc. (SU) | 100 | 365.4 | +265.4% |
| Canadian Natural Re… (CNQ) | 100 | 519.5 | +419.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VET vs CVE vs JPM vs SU vs CNQ
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VET ranks third and is worth considering specifically for dividends.
- 4.1% yield, 3-year raise streak, vs JPM's 1.9%
CVE carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 5 yrs, beta 0.08, yield 2.0%
- Lower volatility, beta 0.08, Low D/E 53.8%, current ratio 1.57x
- Beta 0.08, yield 2.0%, current ratio 1.57x
- Lower P/E (6.2x vs 7.5x)
JPM lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, SU doesn't own a clear edge in any measured category.
CNQ is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 23.9%, EPS growth 81.1%, 3Y rev CAGR -3.7%
- 286.3% 10Y total return vs JPM's 465.8%
- 23.9% revenue growth vs VET's -15.0%
- 23.8% margin vs VET's -44.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.9% revenue growth vs VET's -15.0% | |
| Value | Lower P/E (6.2x vs 7.5x) | |
| Quality / Margins | 23.8% margin vs VET's -44.9% | |
| Stability / Safety | Beta 0.08 vs JPM's 0.94, lower leverage | |
| Dividends | 4.1% yield, 3-year raise streak, vs JPM's 1.9% | |
| Momentum (1Y) | +100.1% vs JPM's +21.8% | |
| Efficiency (ROA) | 11.8% ROA vs VET's -13.8%, ROIC 10.0% vs 3.5% |
VET vs CVE vs JPM vs SU vs CNQ — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
VET vs CVE vs JPM vs SU vs CNQ — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
VET leads in 1 of 6 categories
CNQ leads 1 • CVE leads 0 • JPM leads 0 • SU leads 0 • 4 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — JPM and SU each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 154.6x VET's $1.8B. CNQ is the more profitable business, keeping 23.8% of every revenue dollar as net income compared to VET's -44.9%. On growth, SU holds the edge at +25.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.8B | $49.4B | $280.3B | $52.0B | $40.7B |
| EBITDAEarnings before interest/tax | $1.2B | $12.4B | $81.4B | $21.7B | $20.5B |
| Net IncomeAfter-tax profit | -$814M | $4.6B | $57.0B | $6.3B | $9.7B |
| Free Cash FlowCash after capex | $301M | $4.4B | $100.9B | $7.2B | $6.2B |
| Gross MarginGross profit ÷ Revenue | +35.9% | +19.6% | +60.0% | +55.5% | +30.8% |
| Operating MarginEBIT ÷ Revenue | +20.2% | +14.0% | +25.9% | +27.4% | +26.8% |
| Net MarginNet income ÷ Revenue | -44.9% | +9.4% | +20.4% | +12.2% | +23.8% |
| FCF MarginFCF ÷ Revenue | +16.6% | +8.8% | +36.0% | +13.9% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.4% | -12.8% | — | +25.1% | -14.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -10.9% | +78.7% | +16.0% | +30.1% | -45.3% |
Valuation Metrics
VET leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 12.3x trailing earnings, CNQ trades at a 33% valuation discount to CVE's 18.4x P/E. On an enterprise value basis, VET's 3.9x EV/EBITDA is more attractive than JPM's 18.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.7B | $53.2B | $896.0B | $73.1B | $94.5B |
| Enterprise ValueMkt cap + debt − cash | $2.6B | $63.4B | $1.50T | $83.6B | $108.1B |
| Trailing P/EPrice ÷ TTM EPS | -3.68x | 18.38x | 16.00x | 17.76x | 12.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 11.20x | 6.18x | 14.40x | 6.82x | 7.47x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.90x | — | — |
| EV / EBITDAEnterprise value multiple | 3.92x | 9.04x | 18.36x | 5.09x | 9.55x |
| Price / SalesMarket cap ÷ Revenue | 1.35x | 1.50x | 3.20x | 2.09x | 2.99x |
| Price / BookPrice ÷ Book value/share | 1.08x | 2.28x | 2.47x | 2.33x | 3.00x |
| Price / FCFMarket cap ÷ FCF | 7.32x | 21.86x | 8.88x | 14.77x | 15.69x |
Profitability & Efficiency
CNQ leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CNQ delivers a 24.6% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-34 for VET. SU carries lower financial leverage with a 0.41x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CNQ scores 8/9 vs VET's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -33.7% | +15.2% | +15.9% | +14.0% | +24.6% |
| ROA (TTM)Return on assets | -13.8% | +7.8% | +1.3% | +7.0% | +11.8% |
| ROICReturn on invested capital | +3.5% | +7.9% | +4.5% | +20.1% | +10.0% |
| ROCEReturn on capital employed | +3.3% | +8.2% | +8.9% | +19.5% | +10.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 5 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.59x | 0.54x | 2.60x | 0.41x | 0.44x |
| Net DebtTotal debt minus cash | $1.3B | $14.3B | $599.0B | $14.7B | $19.0B |
| Cash & Equiv.Liquid assets | $19M | $2.7B | $343.3B | $3.6B | $672M |
| Total DebtShort + long-term debt | $1.3B | $17.0B | $942.4B | $18.4B | $19.7B |
| Interest CoverageEBIT ÷ Interest expense | 2.53x | 11.80x | 0.74x | 11.68x | 14.97x |
Total Returns (Dividends Reinvested)
Evenly matched — CVE and JPM each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVE five years ago would be worth $30,275 today (with dividends reinvested), compared to $14,136 for VET. Over the past 12 months, CVE leads with a +100.1% total return vs JPM's +21.8%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs VET's 1.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +31.7% | +62.1% | -0.5% | +37.0% | +33.3% |
| 1-Year ReturnPast 12 months | +45.6% | +100.1% | +21.8% | +62.0% | +42.0% |
| 3-Year ReturnCumulative with dividends | +4.0% | +79.1% | +138.2% | +123.7% | +81.8% |
| 5-Year ReturnCumulative with dividends | +41.4% | +202.8% | +118.2% | +174.3% | +181.1% |
| 10-Year ReturnCumulative with dividends | -39.7% | +109.7% | +465.8% | +176.8% | +286.3% |
| CAGR (3Y)Annualised 3-year return | +1.3% | +21.4% | +33.6% | +30.8% | +22.1% |
Risk & Volatility
Evenly matched — VET and JPM each lead in 1 of 2 comparable metrics.
Risk & Volatility
VET is the less volatile stock with a -0.18 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs VET's 75.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.18x | 0.08x | 0.94x | -0.14x | -0.15x |
| 52-Week HighHighest price in past year | $14.82 | $32.07 | $337.25 | $70.29 | $51.34 |
| 52-Week LowLowest price in past year | $7.00 | $13.47 | $262.71 | $37.23 | $29.30 |
| % of 52W HighCurrent price vs 52-week peak | +75.2% | +88.2% | +95.1% | +87.6% | +88.2% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 48.8 | 59.1 | 41.0 | 44.7 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 7.9M | 7.0M | 3.4M | 7.8M |
Analyst Outlook
Evenly matched — VET and JPM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VET as "Hold", CVE as "Hold", JPM as "Buy", SU as "Buy", CNQ as "Buy". Consensus price targets imply 15.3% upside for SU (target: $71) vs -22.7% for CNQ (target: $35). For income investors, VET offers the higher dividend yield at 4.10% vs JPM's 1.86%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $10.74 | $29.00 | $339.75 | $71.00 | $35.00 |
| # AnalystsCovering analysts | 10 | 27 | 61 | 31 | 37 |
| Dividend YieldAnnual dividend ÷ price | +4.1% | +2.0% | +1.9% | +2.7% | +3.7% |
| Dividend StreakConsecutive years of raises | 3 | 5 | 15 | 10 | 10 |
| Dividend / ShareAnnual DPS | $0.64 | $0.78 | $5.95 | $2.30 | $2.32 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.5% | +3.4% | +3.9% | +3.1% | +1.1% |
VET leads in 1 of 6 categories (Valuation Metrics). CNQ leads in 1 (Profitability & Efficiency). 4 tied.
VET vs CVE vs JPM vs SU vs CNQ: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VET or CVE or JPM or SU or CNQ a better buy right now?
For growth investors, Canadian Natural Resources Limited (CNQ) is the stronger pick with 23.
9% revenue growth year-over-year, versus -15. 0% for Vermilion Energy Inc. (VET). Canadian Natural Resources Limited (CNQ) offers the better valuation at 12. 3x trailing P/E (7. 5x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VET or CVE or JPM or SU or CNQ?
On trailing P/E, Canadian Natural Resources Limited (CNQ) is the cheapest at 12.
3x versus Cenovus Energy Inc. at 18. 4x. On forward P/E, Cenovus Energy Inc. is actually cheaper at 6. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VET or CVE or JPM or SU or CNQ?
Over the past 5 years, Cenovus Energy Inc.
(CVE) delivered a total return of +202. 8%, compared to +41. 4% for Vermilion Energy Inc. (VET). Over 10 years, the gap is even starker: JPM returned +465. 8% versus VET's -39. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VET or CVE or JPM or SU or CNQ?
By beta (market sensitivity over 5 years), Vermilion Energy Inc.
(VET) is the lower-risk stock at -0. 18β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately -617% more volatile than VET relative to the S&P 500. On balance sheet safety, Suncor Energy Inc. (SU) carries a lower debt/equity ratio of 41% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — VET or CVE or JPM or SU or CNQ?
By revenue growth (latest reported year), Canadian Natural Resources Limited (CNQ) is pulling ahead at 23.
9% versus -15. 0% for Vermilion Energy Inc. (VET). On earnings-per-share growth, the picture is similar: Canadian Natural Resources Limited grew EPS 81. 1% year-over-year, compared to -1313. 3% for Vermilion Energy Inc.. Over a 3-year CAGR, CNQ leads at -3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VET or CVE or JPM or SU or CNQ?
Canadian Natural Resources Limited (CNQ) is the more profitable company, earning 24.
5% net margin versus -37. 0% for Vermilion Energy Inc. — meaning it keeps 24. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SU leads at 31. 7% versus 8. 8% for CVE. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VET or CVE or JPM or SU or CNQ more undervalued right now?
On forward earnings alone, Cenovus Energy Inc.
(CVE) trades at 6. 2x forward P/E versus 14. 4x for JPMorgan Chase & Co. — 8. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SU: 15. 3% to $71. 00.
08Which pays a better dividend — VET or CVE or JPM or SU or CNQ?
All stocks in this comparison pay dividends.
Vermilion Energy Inc. (VET) offers the highest yield at 4. 1%, versus 1. 9% for JPMorgan Chase & Co. (JPM).
09Is VET or CVE or JPM or SU or CNQ better for a retirement portfolio?
For long-horizon retirement investors, Canadian Natural Resources Limited (CNQ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
15), 3. 7% yield, +286. 3% 10Y return). Both have compounded well over 10 years (CNQ: +286. 3%, JPM: +465. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VET and CVE and JPM and SU and CNQ?
These companies operate in different sectors (VET (Energy) and CVE (Energy) and JPM (Financial Services) and SU (Energy) and CNQ (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: VET is a small-cap income-oriented stock; CVE is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; SU is a mid-cap deep-value stock; CNQ is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.